165253-29-2

Basic information

• Product Name: 3-(BROMOMETHYL)TETRAHYDROFURAN
• Synonyms: 3-(BROMOMETHYL)TETRAHYDROFURAN;3-(Bromomethyl)tetrahydro...;3-(bromomethyl)tetrahydrofuran(SALTDATA: FREE);3-(Bromomethyl)oxolane;3-Tetrahydrofurylmethyl bromide;Tetrahydro-3-furanylmethyl bromide
• CAS NO: 165253-29-2
• Molecular Formula: C₅H₉BrO
• Molecular Weight: 165.03
• Mol File: 165253-29-2.mol

Chemical Properties

• Boiling Point: 183℃
• Flash Point: 71℃
• Appearance: /
• Density: 1.447
• Vapor Pressure: 1.064mmHg at 25°C
• Refractive Index: n20/D1.494
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(BROMOMETHYL)TETRAHYDROFURAN(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(BROMOMETHYL)TETRAHYDROFURAN(165253-29-2)
• EPA Substance Registry System: 3-(BROMOMETHYL)TETRAHYDROFURAN(165253-29-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• RIDADR: NA 1993 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 165253-29-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(Bromomethyl)tetrahydrofuran is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its ability to react with different functional groups makes it a versatile building block in the synthesis of complex molecules.
Used in Antitumor Agent Synthesis:
3-(Bromomethyl)tetrahydrofuran is used as a reagent in the preparation of thiazoleurea derivatives, which are known for their antitumor properties. These derivatives have potential applications in the treatment of various types of cancer, making 3-(BROMOMETHYL)TETRAHYDROFURAN an important contributor to cancer research and therapeutic development.

InChI:InChI=1/C5H9BrO/c6-3-5-1-2-7-4-5/h5H,1-4H2

Upstream product

• 89181-22-6 3-(chloromethyl)tetrahydrofuran 
• 124391-75-9 3-tetrahydrofuranmethanol 
• 558-13-4 carbon tetrabromide 
• 184849-49-8 (tetrahydrofuran-3-yl)methyl methanesulfonate 

Downstream Products

• 1625669-62-6 4-(1-(3-(trifluoromethyl)phenyl)-2,5-dioxo-3-((tetrahydrofuran-3-yl)methyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)benzonitrile 
• 632625-09-3 3-{2-[5-chloro-2-(tetrahydrofuran-3-ylmethoxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid 
• 1430210-46-0 5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-2-((2-((tetrahydrofuran-3-yl) methoxy)ethyl)thio)-1H-imidazole 
• 1250570-27-4 C₁₃H₁₆O₃ 
• 1574394-59-4 C₁₅H₁₇N₃O₃ 
• 1574394-75-4 C₁₆H₂₀O₅ 
• 1458652-60-2 methyl 2-((3S)-6-((1R)-4-(2,6-dimethyl-4-((tetrahydrofuran-3-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-69-3 2-((3S)-6-((1R)-4-(2,6-dimethyl-4-((tetrahydrofuran-3-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 1458652-61-3 3-((4-bromo-3,5-dimethylphenoxy)methyl)tetrahydrofuran 
• 1431871-82-7 C₂₄H₂₄F₂N₆O₃ 
• 1431871-84-9 C₂₄H₂₅FN₆O₃ 
• 1431871-85-0 C₂₄H₂₅FN₆O₃ 
• 1174718-14-9 4-(3-tetrahydrofuranmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazinyl-7-ethyl formate 
• 646055-78-9 methyl 2-amino-3-(tetrahydrofuran-3-yl)-propionate 

Relevant articles and documents

Tricyclic compound and application thereof

The invention discloses a tricyclic compound and application thereof. The invention specifically discloses a compound as shown in a formula I or pharmaceutically acceptable salt thereof. The tricyclic compound disclosed by the invention has a very good inhibition effect on HDAC (histone deacetylase), especially HDAC6, has relatively good selectivity and can be used for inhibiting proliferation of various tumor cells.

TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS

The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

PURINE DERIVATIVES AS IMMUNOMODULATORS

The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants

THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION

Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteraryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological "reward" process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, wihout resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

Heterocyclic compounds as inhibitors of rotomase enzymes

Compounds of the formula: wherein R1, Y, W, A and R2are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage.

Insecticidal tetrahydrofuran-compound

A tetrahydrofuran-compound is disclosed herein which is represented by the formula (1) STR1 wherein each of X1 and X2 is a hydrogen atom or a methyl group, Y is a hydrogen atom or a carbonyl group substituted by a lower alkyl group (